The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy
Abstract
Walking abnormalities are prominent in Duchenne muscular dystrophy (DMD). We modified the 6‐minute walk test (6MWT) for use as an outcome measure in patients with DMD and evaluated its performance in 21 ambulatory boys with DMD and 34 healthy boys, ages 4 to 12 years. Boys with DMD were tested twice, ∼1 week apart; controls were tested once. The groups had similar age, height, and weight. All tests were completed. Boys who fell recovered rapidly from falls without injury. Mean ± SD [range] 6‐minute walk distance (6MWD) was lower in boys with DMD than in controls (366 ± 83 [125–481] m vs. 621 ± 68 [479–754] m; P < 0.0001; unpaired t‐test). Test‐retest correlation for boys with DMD was high (r = 0.91). Stride length (R2 = 0.89; P < 0.0001) was the major determinant of 6MWD for both boys with DMD and controls. A modified 6MWT is feasible and safe, documents disease‐related limitations on ambulation, is reproducible, and offers a new outcome measure for DMD natural history and therapeutic trials. Muscle Nerve, 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Measuring agreement in method comparison studies
Bland, J. M., & Altman, D. G. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800204 · Cited by 9,619
Measuring agreement in method comparison studies
Bland, J. M., & Altman, D. G. (1999) · Statistical Methods in Medical Research · doi:10.1191/096228099673819272 · Cited by 9,619
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
McDonald, C. M., Abresch, R. T., Carter, G. T., Fowler, W. M., Johnson, E. R., Kilmer, D. D., & Sigford, B. J. (1995) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199509001-00003 · Cited by 1,069
Self-citationRedelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029 · cited 1×
“A study in patients with chronic obstructive pulmonary disease indicates that mean relative improvements of 10% to 15% in 6MWD are consistent with discernable improvements in well-being.(34) These data are supported by the results from placebo-controlled, registration-directed, randomized studies of bosentan, laronida…”
ResultSix-Minute Walk Test in Children and Adolescents
Geiger, R., Strasak, A., Treml, B., Gasser, K., Kleinsasser, A., Fischer, V., Geiger, H., Loeckinger, A., & Stein, J. I. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.12.052 · Cited by 653
How to Assess the Reliability of Measurements in Rehabilitation
Lexell, J. E., & Downham, D. Y. (2005) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/01.phm.0000176452.17771.20 · Cited by 627
Muenzer, J., Wraith, J. E., Beck, M., Giugliani, R., Harmatz, P., Eng, C. M., Vellodi, A., Martin, R., Ramaswami, U., Gucsavas-Calikoglu, M., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000232477.37660.fb · Cited by 584
Wraith, J. E., Clarke, L. A., Beck, M., Kolodny, E. H., Pastores, G. M., Muenzer, J., Rapoport, D. M., Berger, K. I., Swiedler, S. J., Kakkis, E. D., et al. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.01.046 · Cited by 547
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Crespo, C. J. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440010113015 · Cited by 504
Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy
Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R., Florence, J., King, W. M., Pandya, S., Robison, J., Schierbecker, J., et al. (1989) · Neurology · doi:10.1212/wnl.39.4.475 · Cited by 353
Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?
Temple, R. (1999) · JAMA · doi:10.1001/jama.282.8.790 · Cited by 337
The 6-minute walk test: normal values for children of 4-11 years of age
Lammers, A. E., Hislop, A. A., Flynn, Y., & Haworth, S. G. (2008) · Archives of Disease in Childhood · doi:10.1136/adc.2007.123653 · Cited by 315
Standard Reference for the Six-Minute-Walk Test in Healthy Children Aged 7 to 16 Years
Li, A. M., Yin, J., Au, J. T., So, H. K., Tsang, T., Wong, E., Fok, T. F., & Ng, P. C. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200607-883oc · Cited by 298
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
King, W. M., Ruttencutter, R., Nagaraja, H. N., Matkovic, V., Landoll, J., Hoyle, C., Mendell, J. R., & Kissel, J. T. (2007) · Neurology · doi:10.1212/01.wnl.0000260974.41514.83 · Cited by 283
Griggs, R. C. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530160047012 · Cited by 279
Physical Activity, Health Impairments, and Disability in Neuromuscular Disease
McDonald, C. M. (2002) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-200211001-00012 · Cited by 224
Self-citationReliability and feasibility of the six minute walk test in subjects with myotonic dystrophy
Kierkegaard, M., & Tollbäck, A. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.08.003 · Cited by 112
Utility of a step activity monitor for the measurement of daily ambulatory activity in children
McDonald, C. M., Widman, L. M., Abresch, R. T., Walsh, S. A., & Walsh, D. D. (2005) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2004.10.011 · Cited by 105
Self-citationFDA: Evidentiary standards for drug development and approval
Katz, R. G. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.3.307 · Cited by 104
Intermittent Prednisone Therapy in Duchenne Muscular Dystrophy: A Randomized Controlled Trial
Beenakker, E. A. C., Fock, J. M., Tol, M. J. V., Maurits, N. M., Koopman, H. M., Brouwer, O. F., & van der Hoeven, J. H. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.128 · Cited by 100
Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research
Muntoni, F., Fisher, I. B., Morgan, J. E., & Abraham, D. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00101-3 · Cited by 81
Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy.
Sockolov, R., Irwin, B., Dressendorfer, R., et al. (1977) · PubMed · Cited by 64
Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation
Pradhan, S., Ghosh, D., Srivastava, N. K., Kumar, A., Mittal, B., Pandey, C. M., & Singh, U. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0212-1 · Cited by 61
Challenges in drug development for muscle disease: A stakeholders' meeting
Mendell, J. R., Csimma, C., McDonald, C. M., Escolar, D. M., Janis, S., Porter, J. D., Hesterlee, S. E., & Howell, R. R. (2006) · Muscle & Nerve · doi:10.1002/mus.20686 · Cited by 35
Self-citationRoush, J. R., Guy, J., & Purvis, M. (2006) · Internet Journal of Allied Health Sciences and Practice · doi:10.46743/1540-580x/2006.1109 · Cited by 18
Cited by
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
McDonald, C. M., Campbell, C., Torricelli, R. E., Finkel, R. S., Flanigan, K. M., Goemans, N., Heydemann, P., Kaminska, A., Kirschner, J., Muntoni, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31611-2 · Cited by 452
Self-citationAtaluren treatment of patients with nonsense mutation dystrophinopathy
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., Connolly, A. M., Day, J. W., Flanigan, K. M., Goemans, N., et al. (2014) · Muscle & Nerve · doi:10.1002/mus.24332 · Cited by 428
Self-citation
Metadata
- Authors
- McDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Elfring, G. L., Atkinson, L., Reha, A., Hirawat, S., & Miller, L. L.
- Venue
- Muscle & Nerve
- Publisher
- Wiley
- Published
- 2009-11-25
- Volume
- 41
- Issue
- 4
- Pages
- 500-510
- ISSN
- 0148-639X (ISSN-L)
- 1097-4598
- OpenAlex
- W2065376245
- Cited by
- 397
- References
- 29
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.